Clinical Efficacy Evaluation of Sitagliptin Sodium in Treating Hypertriglyceridemia in Patients with Hypertriglyceridemia-Associated Pancreatitis

INTERVENTION: Fenofibrate Group:Oral fenofibrate tablets, once daily, 0.2g each time;Chiglitazar Sodium Group:Take Siglitin Sodium tablets orally, once daily, 48 mg each time;Fenofibrate & Chiglitazar Sodium Combination Group:Oral Fenofibrate tablet (0.2g per dose) in combination with Chiglitazar Sodium tablet (48mg per dose), once daily; CONDITION: Hyperlipidemic Acute Pancreatitis PRIMARY OUTCOME: Lipid Metabolism Markers (Triglycerides, Cholesterol, HDL, LDL,,etc);Inflammatory markers (C‐reactive protein, erythrocyte sedimentation rate, interleukin‐6, tumor necrosis factor, etc.); SECONDARY OUTCOME: Glucose metabolism indicators (such as fasting venous blood glucose, 2‐hour postprandial blood glucose, etc.);Body composition analysis indicators (BMI, waist‐to‐hip ratio, etc.);Total Score of Treatment Satisfaction Questionnaire for Medicine;Recurrence Rate; INCLUSION CRITERIA: 1. Age: Male individuals aged 18‐65 or non‐pregnant females; 2. Meet the diagnostic criteria of HTG‐AP; 3. Have not used fenofibrate or sitagliptin sodium within the recent 3 months; 4. Have not participated in any other treatment studies for the same disease within the previous 3 months; 5. Agree to sign the informed consent form, and the informed consent form must be signed before enrollment; 6. All participants were recruited from Xiangya Hospital of Central South University.